Revolution Medicines, Inc. (Nasdaq: RVMD) presented Phase 1/2 clinical trial data for zoldonrasib, its oral RAS(ON) G12D-selective inhibitor, in two ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE